Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
Rhea-AI Summary
Tango Therapeutics (Nasdaq:TNGX) priced an upsized underwritten public offering of 18,166,667 common shares and pre-funded warrants to purchase up to 1,833,395 shares at $30.00 per share and $29.999 per warrant.
Gross proceeds are expected to be about $600 million, with a 30-day option for underwriters to buy up to 3,000,009 additional shares. Closing is expected around June 11, 2026.
Positive
- Upsized equity and warrant offering to raise about $600 million gross
- 30-day underwriter option could bring in additional capital if exercised
Negative
- Issuance of 18.17M shares and 1.83M warrants dilutes existing shareholders
- Underwriters’ option for 3,000,009 extra shares adds further dilution risk
News Market Reaction – TNGX
In the Jun 10 session, TNGX declined 9.13%, reflecting a notable negative market reaction. Argus tracked a trough of -11.9% from its starting point during tracking. Our momentum scanner triggered 51 alerts that day, indicating high trading interest and price volatility. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the pricing of an underwritten offering of 18,166,667 shares of its common stock and pre-funded warrants to purchase up to 1,833,395 shares of its common stock (the “Offering”). The offering price of each share of common stock is
J.P. Morgan, Leerink Partners, Cantor and Stifel are acting as joint bookrunning managers for the Offering.
The Offering is being made pursuant to an effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (the “SEC”). A preliminary prospectus supplement, accompanying prospectus and a free writing prospectus relating to the Offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. A final prospectus supplement and accompanying prospectus relating to the Offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement, accompanying prospectus and the free writing prospectus relating to the Offering may also be obtained, when available, by contacting: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109; by telephone at (800) 808-7525 ext. 6105; or by email at syndicate@leerink.com; Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by e-mail at prospectus@cantor.com; and Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the timing and closing of the Offering, the potential exercise by the underwriters of the option to purchase additional shares, and the expected gross proceeds from the Offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
The forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by the forward-looking statements contained in this press release. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Tango’s most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Tango’s other filings with the SEC, including those contained or incorporated by reference in the prospectus supplement, accompanying prospectus and any free writing prospectus related to the Offering filed with the SEC. The forward-looking statements contained in this press release represent Tango’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Tango explicitly disclaims any obligation to update any forward-looking statements, except as required by law.
Investors:
Elizabeth Hickin
IR@tangotx.com
media@tangotx.com
Media:
1AB
Amanda Lazaro
amanda@1abmedia.com
